Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk-benefit ratioJulie Delyon,Olivier MichielinLANCET ONCOLOGY(2024)引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要